Biomed Industries, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website: http://www.biomedind.com

Clinical Trials

Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese

Phase 2

Not yet recruiting

Conditions: Obesity and Overweight

Interventions: Drug: Tirzepatide
Drug: NA-931
Drug: NA-931 150 mg + no Tirzepatide

First Posted Date: 2024-12-13

Last Posted Date: 2024-12-17

Lead Sponsor: Biomed Industries, Inc.

Target Recruit Count: 224

Registration Number: NCT06732245

Locations: 🇺🇸
Biomed Research Unit #90067-102, Los Angeles, California, United States
🇺🇸
Biomed Research Unit # 92121-103, San Diego, California, United States
🇺🇸
Biomed Research Unit # 94104-101, San Francisco, California, United States

and more 14 locations

Phase 1 to Study Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NA-931 in Obese Participants and Patients With Type 2 Diabetes Mellitus

Phase 1

Completed

Conditions: Overweight or Obesity
Type 2 Diabetes

Interventions: Drug: NA-931
Drug: Placebo

First Posted Date: 2024-09-27

Last Posted Date: 2024-09-27

Lead Sponsor: Biomed Industries, Inc.

Target Recruit Count: 74

Registration Number: NCT06615700

Locations: 🇦🇺
Biomed Industries Pty Limited- Clinical Testing Site 1, Camperdown, New South Wales, Australia
🇦🇺
Biomed Industries, Pty Limited Testing Site 2, Parkville, Victoria, Australia

Phase 2 Trials of NA-931 to Study Subjects Who Are Obese With at Least One Weight-related Comorbid Condition

Phase 2

Recruiting

Conditions: Body Weight Changes
Body Weight
Obesity
Weight Loss

Interventions: Drug: NA-931, dose 1, daily and orally
Drug: NA-931 dose 3, daily and orally
Drug: NA-931, dose2, daily and orally
Drug: NA-931 dose 4, daily and orally

First Posted Date: 2024-08-21

Last Posted Date: 2024-08-21

Lead Sponsor: Biomed Industries, Inc.

Target Recruit Count: 125

Registration Number: NCT06564753

Locations: 🇦🇺
Biomed Investigational Site, Melbourne, Victoria, Australia

A Phase 3 Randomized Double Blind Efficacy and Safety Study of Oral Polio Vaccine and NA-831 for Covid-19

Phase 3

Conditions: Covid19
SARS (Severe Acute Respiratory Syndrome)
SARS-CoV Infection
SARS-CoV-2

Interventions: Biological: Comparable Placebo
Drug: NA-831
Drug: Comparable Placebo of drug
Combination Product: Combination of oral polio vaccine and NA-831
Combination Product: Comparable Placebo of Oral Polio Vaccine and Placebo of drug

First Posted Date: 2020-09-07

Last Posted Date: 2020-09-09

Lead Sponsor: Biomed Industries, Inc.

Target Recruit Count: 3600

Registration Number: NCT04540185

Locations: 🇺🇸
Coronavirus Research Institute- Testing Site, Los Angeles, California, United States
🇺🇸
Coronavirus Research Institute, Sunnyvale, California, United States
🇺🇸
Coronavirus Research Testing Site, San Francisco, California, United States

and more 4 locations

Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and NA-831

Phase 1

Conditions: Severe Acute Respiratory Syndrome of Upper Respiratory Tract
Covid19
Severe Acute Respiratory Syndrome
Severe Acute Respiratory Infection
Neurodegeneration
Corona Virus Infection
Neuroinflammatory Response
Severe Acute Respiratory Syndrome (SARS) Pneumonia

Interventions: Drug: Placebo- 0.10 mg/kg
Drug: Placebo- 1.00 mg/kg
Drug: Placebo- 2.00 mg/kg
Drug: Placebo- 0.20 mg/kg
Combination Product: Placebo 0.20 mg + 2.00 mg/kg
Combination Product: Placebo 0.10 mg + 1.00 mg/kg

First Posted Date: 2020-07-21

Last Posted Date: 2020-07-21

Lead Sponsor: Biomed Industries, Inc.

Target Recruit Count: 45

Registration Number: NCT04480333

Locations: 🇺🇸
Coronavirus Research Institute, Sunnyvale, California, United States

NA-831, Atazanavir and Dexamethasone Combination Therapy for the Treatment of COVID-19 Infection

Phase 2

Conditions: Severe Acute Respiratory Infection
Coronavirus Infection
Severe Acute Respiratory Syndrome Coronavirus 2

Interventions: Combination Product: NA-831 and Atazanavir
Combination Product: NA-831and Dexamethasone
Combination Product: Atazanavir and Dexamethasone

First Posted Date: 2020-06-30

Last Posted Date: 2022-02-16

Lead Sponsor: Biomed Industries, Inc.

Target Recruit Count: 525

Registration Number: NCT04452565

Locations: 🇺🇸
Coronavirus Research Institute, Orange, California, United States
🇺🇸
Coronavirus Research Institute- Testing Site, Fort Sam Houston, Texas, United States
🇺🇸
Coronavirus Research Institute-Testing Site, Tacoma, Washington, United States

and more 2 locations

A Double-Blind, Placebo-Controlled Safety and Efficacy Study of NA-831

Phase 2

Completed

Conditions: Alzheimer Dementia
Tauopathies
Neurodegenerative Diseases
Alzheimer Disease
Cognitive Disorder
Mild Cognitive Impairment
Dementia With Lewy Bodies
Cognitive Impairment
Dementia, Vascular
Neurocognitive Disorders

Interventions: Drug: Placebo oral capsule QD
Drug: NA-831 (Traneurocin) 20 mg QD
Drug: NA-831 (Traneurocin) 40 mg QD
Drug: N-831(Traneurocin) 10 mg QD

First Posted Date: 2018-05-29

Last Posted Date: 2020-06-30

Lead Sponsor: Biomed Industries, Inc.

Target Recruit Count: 126

Registration Number: NCT03538522

Locations: 🇳🇿
NeuroActiva Testing Facility of NeuroActiva (New Zealand) Ltd, Auckland, New Zealand
🇳🇿
NeuroActiva-Clinical Research Unit, Auckland, New Zealand

Prev
1
Next

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy